{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:36:31Z","timestamp":1761093391737,"version":"build-2065373602"},"reference-count":67,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2012,1,20]],"date-time":"2012-01-20T00:00:00Z","timestamp":1327017600000},"content-version":"vor","delay-in-days":50,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:p>A number of novel anticoagulants are moving through various stages of drug development. Recently, the United States Food and Drug Administration approved the oral direct thrombin inhibitor dabigatran etexilate to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Although dabigatran offers a number of advantages over existing oral and parenteral anticoagulants, challenges exist for clinicians who must ensure its safe and effective use. Limited data are available on dabigatran use in patients with renal dysfunction and in obese patients, or in combination with other drugs. Clinical experience is lacking in populations for whom anticoagulants are routinely used, such as patients with a previous stroke, acute coronary syndromes, or pregnancy\u2010associated thrombosis, or those requiring ablation therapy. More important, clinicians will be faced with incorporating dabigatran into hospital guidelines for transitioning between oral and parenteral anticoagulants, measuring anticoagulant intensity, managing anticoagulant\u2010related hemorrhage, ensuring safe use around neuraxial anesthesia, and implementing computer\u2010based alert or warning systems. Since anticoagulants are ubiquitously used in the prevention or treatment of venous and arterial thrombosis, both clinicians and patients must be provided structured education on dabigatran's benefits and limitations. In this article, our goal was to provide practical advice to enhance clinician understanding of dabigatran, identify clinical and operational challenges to its use, and offer system improvements that can ensure safe and effective use of dabigatran.<\/jats:p>","DOI":"10.1592\/phco.31.12.1232","type":"journal-article","created":{"date-parts":[[2011,11,28]],"date-time":"2011-11-28T13:02:13Z","timestamp":1322485333000},"page":"1232-1249","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Dabigatran Etexilate in Clinical Practice: Confronting Challenges to Improve Safety and Effectiveness"],"prefix":"10.1002","volume":"31","author":[{"given":"Michael P.","family":"Gulseth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann K.","family":"Wittkowsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Fanikos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah A.","family":"Spinler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William E.","family":"Dager","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edith A.","family":"Nutescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,20]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-0670"},{"key":"e_1_2_1_3_2","unstructured":"Institute for Safe Medication Practices.ISMP's list of high\u2010alert medications. Available fromhttp:www.ismp.orgtoolshighalertmedications.pdf. Accessed May 29 2010."},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp040534"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.30.4.327"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.127.5.1515"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.2010.01216.x"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp080507"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905561"},{"key":"e_1_2_1_10_2","unstructured":"U.S. Food and Drug Administration.FDA approves Pradaxa (dabigatran etexilate) to prevent stroke in people with atrial fibrillation. FDA news release.Available fromhttp:www.fda.govNewsEventsNewsroomPressAnnouncementsucm230241.htm. Accessed January 15 2011."},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-062209-095159"},{"key":"e_1_2_1_12_2","unstructured":"Boehringer Ingelheim Pharmaceuticals.Advisory committee briefing document. Available fromhttp:www.fda.govdownloadsAdvisoryCommitteesCommitteesMeetingMaterialsDrugsCardiovascularandRenalDrugsAdvisoryCommitteeUCM226009.pdf. Accessed February 16 2011."},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH09-11-0758"},{"key":"e_1_2_1_14_2","unstructured":"U.S. Food and Drug Administration.Briefing information for the September 20 2010 meeting of the cardiovascular and renal drugs advisory committee. Available fromhttp:www.fda.govdownloadsAdvisoryCommitteesCommitteesMeetingMaterialsDrugsCardiovascularandRenalDrugsAdvisoryCommitteeUCM226011.pdf. Accessed January 10 2011."},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2007.02899.x"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.107.019083"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.2165\/11318170-000000000-00000"},{"volume-title":"Pradaxa (dabigatran etexilate) package insert","year":"2010","author":"Boehringer Ingelheim Pharmaceuticals.","key":"e_1_2_1_18_2"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-0674"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02748.x"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61445-7"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.arth.2008.01.132"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-0675"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp060133"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-0689"},{"volume-title":"Lovenox (enoxaparin sodium injection) package insert","year":"2009","author":"Sanofi Aventis Pharmaceuticals.","key":"e_1_2_1_26_2"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/AAP.0b013e3181c15c70"},{"volume-title":"Data on file. Epidural or spinal catheter use","year":"2011","author":"Boehringer Ingelheim Pharmaceuticals, Inc.","key":"e_1_2_1_28_2"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2044.2007.05195.x"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/ACO.0b013e32832eb8ab"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.mbc.0000114437.81125.2b"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3148.2009.00913.x"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2006.08.002"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-409X(02)00171-0"},{"key":"e_1_2_1_35_2","unstructured":"OesterheldJ.P\u2010glycoprotein (PGP) table\u2014the effect of drugs and foods. May 22 2009. Available fromhttp:www.genemedrx.comPGPtable.php. Accessed Jauary 14 2010."},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.psy.46.5.464"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.107.181486"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-0720"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512143332401"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1159\/000319886"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.977546"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-010-0153-2"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/eum120"},{"key":"e_1_2_1_44_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10840-010-9539-8"},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2011.01.020"},{"key":"e_1_2_1_46_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1007378"},{"journal-title":"Eur Heart J.","article-title":"Dabigatran vs placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double\u2010blind, phase II trial [published online ahead of print May 7, 2011]","author":"Oldgren J","key":"e_1_2_1_47_2"},{"volume-title":"Data on file. What was the weight of the lightest and heaviest patients in RE\u2010LY?","year":"2011","author":"Boehringer Ingelheim Pharmaceuticals, Inc.","key":"e_1_2_1_48_2"},{"key":"e_1_2_1_49_2","doi-asserted-by":"publisher","DOI":"10.1177\/1076029609343004"},{"volume-title":"Data on file. Conversion between warfarin and Pradaxa","year":"2011","author":"Boehringer Ingelheim Pharmaceuticals, Inc.","key":"e_1_2_1_50_2"},{"key":"e_1_2_1_51_2","doi-asserted-by":"publisher","DOI":"10.2165\/11316560-000000000-00000"},{"key":"e_1_2_1_52_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1006221"},{"key":"e_1_2_1_53_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa042991"},{"key":"e_1_2_1_54_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-153-10-201011160-00005"},{"key":"e_1_2_1_55_2","unstructured":"U.S Food and Drug Administration.Approved risk evaluation and mitigation strategies. NDA 22\u2013512 Pradaxa (dabigatran etexilate mesylate) capsules risk evaluation and mitigation strategy. Available fromhttp:www.fda.govdownloadsDrugsDrugSafetyPostmarketDrugSafetyInformationforPatientsandProvidersUCM232057.pdf. Accessed January 31 2011."},{"key":"e_1_2_1_56_2","unstructured":"U.S Food and Drug Administration.Pradaxa (dabigatran etexilate mesylate) capsules: special storage and handling requirements. MedWatch: the FDA safety information and adverse event reporting program. Available fromhttp:www.fda.govSafetyMedWatchSafetyInformationSafetyAlertsforHumanMedicalProductsucm249005.htm. Accessed April 1 2011."},{"issue":"4","key":"e_1_2_1_57_2","first-page":"2","article-title":"Pradaxa capsules have a short expiration date after bottle opened [newsletter","volume":"16","author":"Institute for Safe Medication Practices.","year":"2011","journal-title":"ISMP Medication Safety Alert"},{"key":"e_1_2_1_58_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.164.18.2044"},{"key":"e_1_2_1_59_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-008-0690-1"},{"key":"e_1_2_1_60_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1L098"},{"key":"e_1_2_1_61_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2010.239"},{"key":"e_1_2_1_62_2","unstructured":"The Joint Commission.The Joint Commission national patient safety goals July 1 2010. Available fromhttp:www.jointcommission.orgNRrdonlyres868C9E07\u2010037F\u2010433D\u20108858\u20100D5FAA4322F20July2010NPSGs_Scoring_HAP2.pdf. Accessed August 7 2010."},{"key":"e_1_2_1_63_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.31.12.2966"},{"key":"e_1_2_1_64_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2010.263"},{"key":"e_1_2_1_65_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2261-10-21"},{"key":"e_1_2_1_66_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1P092"},{"key":"e_1_2_1_67_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra050100"},{"key":"e_1_2_1_68_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.5.565"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.31.12.1232","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.31.12.1232","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:25:08Z","timestamp":1761045908000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.31.12.1232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":67,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["10.1592\/phco.31.12.1232"],"URL":"https:\/\/doi.org\/10.1592\/phco.31.12.1232","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"type":"print","value":"0277-0008"},{"type":"electronic","value":"1875-9114"}],"subject":[],"published":{"date-parts":[[2011,12]]},"assertion":[{"value":"2012-01-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}